Adaptive Biotechnologies (ADPT) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Core Insights - Adaptive Biotechnologies reported revenue of $47.46 million for the quarter ended December 2024, marking a year-over-year increase of 3.7% [1] - The company's EPS for the same period was -$0.23, an improvement from -$0.30 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $46.43 million by 2.23%, and the EPS also surpassed the consensus estimate of -$0.26 by 11.54% [1] Performance Metrics - The ClonoSEQ test volume was reported at 20,945, which was below the average estimate of 22,150 by three analysts [4] - Total Minimal Residual Disease (MRD) revenues were $40.15 million, exceeding the average estimate of $38.24 million by three analysts, representing a significant year-over-year increase of 30.4% [4] - Total Immune Medicine revenues were reported at $7.31 million, which fell short of the average estimate of $7.90 million and indicated a year-over-year decline of 51.3% [4] Stock Performance - Shares of Adaptive Biotechnologies have increased by 18.9% over the past month, outperforming the Zacks S&P 500 composite, which saw a change of 4.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]